US Patent 8,778,373: Scope, Claims, Expiration, and Patent Landscape for Extended-Release Calcifediol

US Patent 8,778,373 protects methods of administering extended-release 25-hydroxyvitamin D3, also known as calcifediol or calcidiol, using pharmacokinetic limits rather than a narrowly defined formulation. The claims require controlled release that reduces early exposure relative to bolus intravenous or immediate-release oral dosing, or delays the time to maximum concentration. The principal commercial product associated with this technology is Rayaldee, an extended-release calcifediol product marketed by OPKO Health.

The patent is method-of-treatment intellectual property. It does not, based on the claims provided, claim every calcifediol formulation or every use of calcifediol. Infringement depends on the accused product and dosing regimen satisfying the claimed pharmacokinetic comparison, patient population, dose, duration, and treatment objective.

What does US Patent 8,778,373 cover?

US Patent 8,778,373 covers controlled-release administration of a vitamin D compound comprising 25-hydroxyvitamin D3. The independent claim uses two alternative pharmacokinetic pathways:

A reduced Cmax24hr/C24hr ratio compared with bolus IV or immediate-release oral administration.
An increased Tmax compared with bolus IV or immediate-release oral administration.

The patent therefore targets the pharmacokinetic behavior produced by extended release, not merely the presence of calcifediol in a dosage form.

Claim element	Requirement
Active compound	Vitamin D compound comprising 25-hydroxyvitamin D3
Administration	Controlled release
Comparator	Equivalent amount administered by bolus IV injection and/or immediate-release oral dosage form
Cmax pathway	Reduced ratio of maximum serum concentration within 24 hours to concentration at 24 hours
Tmax pathway	Increased time to maximum plasma concentration within a dose interval
Patient	Human patient for the dependent clinical claims
Dose	1 to 100 micrograms per day in claims 3, 11, and 19
Duration	At least one month in claims 4, 12, and 20
Clinical population	Vitamin D deficient, vitamin D replete, or secondary hyperparathyroidism associated with vitamin D deficiency
Therapeutic objective	Raise serum 25(OH)D to at least 30 ng/mL, lower PTH, or prevent serum 25(OH)D from falling below 30 ng/mL

The patent is significant because a product can potentially fall within the claim scope even if its formulation composition differs from the commercial reference product. The focus is the resulting pharmacokinetic profile and the method of administration.

How are the 20 claims organized?

Claims 1, 2, and 10 provide the principal claim architecture. The remaining claims add dosing, duration, patient status, treatment goals, and pharmacokinetic thresholds.

Claim 1: broad alternative pharmacokinetic protection

Claim 1 is the broadest independent claim in the provided set. It requires controlled release and either:

a lower Cmax24hr/C24hr ratio; or
a higher Tmax.

The use of “and/or” creates alternative infringement routes. A product may implicate the claim through the Cmax ratio, the Tmax comparison, or both.

The comparison is against an equivalent amount of calcifediol administered by bolus IV injection and/or immediate-release oral dosage form. This creates several technical issues:

The dose must be equivalent.
The comparator route and dosage form must be established.
The relevant pharmacokinetic data must be normalized sufficiently for comparison.
The dose interval must be defined for the Tmax analysis.
The accused product must be administered in a controlled-release manner.

Claims 2 and 10: separate Cmax and Tmax branches

Claim 2 narrows claim 1 to the Cmax24hr/C24hr limitation. Claim 10 narrows claim 1 to the Tmax limitation.

These claims create two independent enforcement theories:

Claim branch	Required result
Cmax branch	Lower Cmax24hr/C24hr ratio
Tmax branch	Longer Tmax

A generic or follow-on product could avoid one branch but still face exposure under the other if its pharmacokinetic profile satisfies the remaining limitation.

Claims 3 through 9: dose, duration, and clinical use

Claims 3 through 9 focus on the Cmax branch. They require, in various combinations:

1 to 100 micrograms per day;
administration for at least one month;
treatment of vitamin D-deficient patients;
treatment of vitamin D-replete patients;
treatment of secondary hyperparathyroidism associated with vitamin D deficiency;
raising serum 25(OH)D to at least 30 ng/mL;
reducing the Cmax24hr/C24hr ratio by at least 20%.

Claim 9 provides the clearest quantitative limitation in this branch. A reduction “by a factor of at least 20%” will require a defined calculation against the selected comparator.

Claims 11 through 17: Tmax, dose, duration, and clinical use

Claims 11 through 17 mirror the Cmax branch but rely on delayed Tmax. Claim 17 requires that Tmax increase by at least 25%.

The most commercially relevant limitations are:

daily administration of 1 to 100 micrograms;
treatment for at least one month;
treatment of deficient or replete patients;
treatment of secondary hyperparathyroidism;
achieving serum 25(OH)D of at least 30 ng/mL;
increasing Tmax by at least 25%.

Claims 18 through 20: treatment objectives

Claims 18 through 20 address clinical endpoints:

preventing serum 25(OH)D from falling below 30 ng/mL;
administering 1 to 100 micrograms per day;
continuing administration for at least one month.

Claims 18 and 20 may be important in product-use litigation because the treatment objective could be established through labeling, clinical protocols, physician instructions, or actual use evidence.

What is the technical scope of the pharmacokinetic limitations?

The patent does not define controlled release solely by a manufacturing feature such as a polymer matrix, coating, capsule, bead, or multiparticulate system. Instead, it describes controlled release through observed serum or plasma concentration behavior.

Cmax24hr/C24hr ratio

The ratio compares:

[ \text{Cmax}{24hr}/\text{C}{24hr} ]

Cmax24hr is the highest serum concentration observed during the first 24 hours after administration. C24hr is the concentration measured at 24 hours.

A lower ratio indicates a less pronounced early peak relative to the 24-hour concentration. The limitation is directed at reducing peak-to-trough fluctuation and maintaining exposure later in the dosing interval.

Claim 9 adds a 20% reduction threshold. A potential infringement analysis would compare the ratio for the controlled-release product with the ratio produced by the specified immediate-release or IV comparator:

[ \text{Reduction} = \frac{\text{Comparator ratio} - \text{Controlled-release ratio}} {\text{Comparator ratio}} ]

The patent does not appear, from the claims supplied, to require a particular absolute Cmax, area under the curve, half-life, or bioavailability.

Tmax

Tmax is the time required for plasma concentration to reach its maximum within the dose interval. A delayed Tmax indicates slower absorption or controlled release.

Claim 17 requires at least a 25% increase in Tmax. The relevant calculation is:

[ \text{Increase} = \frac{\text{Controlled-release Tmax} - \text{Comparator Tmax}} {\text{Comparator Tmax}} ]

Tmax can be sensitive to sampling schedules. Sparse sampling may make the observed Tmax less precise, while different dose intervals or study designs may complicate the comparison.

Potential claim-construction disputes

The most likely technical disputes concern:

the meaning of “equivalent amount”;
whether an immediate-release comparator must be administered orally;
whether IV bolus data can be used when the accused product is oral;
whether C24hr must be measured at exactly 24 hours;
whether Tmax is measured within a fixed dose interval;
whether population-average or individual-subject data control;
whether the pharmacokinetic result must be inherent in the product or expressly intended;
whether the treatment method requires actual achievement of the stated serum 25(OH)D or PTH result.

These limitations may make infringement fact-intensive but can also create validity challenges based on indefiniteness, written description, enablement, or lack of predictable boundaries.

What are the likely validity strengths and weaknesses?

The patent has a strong commercial position where the approved product label and clinical data align with the claimed controlled-release profile. Its principal weakness is that the claims rely heavily on comparative pharmacokinetics and clinical administration details.

Issue	Patent strength	Risk area
Active ingredient	25-hydroxyvitamin D3 is clearly identified	Limited protection against non-calcifediol vitamin D compounds
Controlled release	Functional result can cover multiple formulations	Scope may depend on reproducible testing
Cmax limitation	Quantitative claim 9 provides a measurable threshold	Comparator selection and measurement methodology
Tmax limitation	Captures delayed absorption	Sampling schedule and dose interval
Dose	1 to 100 micrograms per day covers commercial dosing	Does not reach doses outside the range
Duration	At least one month supports chronic therapy	Short-course uses may fall outside dependent claims
Clinical use	Covers deficiency, replete patients, and secondary hyperparathyroidism	Actual patient use and label language may control proof
Serum target	30 ng/mL threshold aligns with vitamin D treatment objectives	Patient variability and clinical measurement differences

A Paragraph IV challenger would likely focus on prior art showing extended-release calcifediol or other vitamin D compounds, pharmacokinetic optimization, and treatment of secondary hyperparathyroidism. It could also challenge whether the claimed pharmacokinetic results distinguish the invention from routine formulation development.

What drug is associated with US Patent 8,778,373?

The patent is associated with extended-release calcifediol, marketed in the United States as Rayaldee. Rayaldee is an oral extended-release formulation of calcifediol indicated to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The FDA label identifies a 30-microgram extended-release capsule administered once daily, with potential dose adjustment to 60 micrograms daily.[2]

The approved product aligns with several dependent claim limitations:

25-hydroxyvitamin D3 as the active compound;
daily oral administration;
chronic treatment;
secondary hyperparathyroidism associated with chronic kidney disease and vitamin D insufficiency;
a serum 25(OH)D treatment target.

The claims provided are broader than the approved indication in some respects because they cover vitamin D-replete patients and prevention of serum 25(OH)D levels below 30 ng/mL.

What is the Orange Book status of US Patent 8,778,373?

US Patent 8,778,373 has been associated with Rayaldee patent protection and should be evaluated against the current FDA Orange Book listing for NDA 208010. Orange Book listings can change through delisting, patent-expiration updates, pediatric exclusivity, or product-specific regulatory submissions.[1]

For an ANDA applicant, the practical question is whether the patent is listed for the reference drug and whether the proposed label includes a use or dosing regimen covered by the claims. If listed, an ANDA applicant generally must certify under Paragraph IV that the patent is invalid, unenforceable, or will not be infringed, unless it omits the relevant method of use through a section viii statement.

The patent claims are method claims, which increases the importance of:

the proposed ANDA labeling;
the reference product’s listed indication;
the applicant’s proposed dosage regimen;
whether the applicant seeks approval for all labeled uses;
whether a permitted carve-out can remove the patented method.

When does US Patent 8,778,373 lose exclusivity?

The patent’s effective expiration date must be determined from the USPTO patent-term calculation, including any patent-term adjustment and potential patent-term extension. The nominal term is generally measured from the earliest effective nonprovisional filing date under the 20-year patent-term framework.[3]

For commercial planning, the patent should be treated as a late-2020s asset. The exact generic-entry date depends on:

the patent’s calculated expiration date;
any pediatric exclusivity;
Orange Book status;
Paragraph IV litigation;
a settlement agreement;
a final court judgment;
FDA approval timing for an ANDA.

Patent expiry does not automatically eliminate all Rayaldee exclusivity. Other formulation, manufacturing, or method-of-use patents may create separate barriers.

How many patents cover Rayaldee and extended-release calcifediol?

The Rayaldee estate has included multiple patent families directed to extended-release calcifediol, formulation technology, pharmacokinetics, and therapeutic use. Patent numbers associated with a product can differ by regulatory listing, continuation practice, and jurisdiction.

The principal categories are:

Patent category	Relevance to Rayaldee
Controlled-release pharmacokinetics	Covers delayed Tmax and reduced early peak exposure
Extended-release formulation	May cover capsule composition, release profile, or excipient structure
Method of treatment	Covers vitamin D deficiency, secondary hyperparathyroidism, and serum 25(OH)D targets
Manufacturing	May cover preparation of calcifediol dosage forms or controlled-release systems
Continuation patents	Can preserve similar subject matter with altered claim language

US Patent 8,778,373 is therefore one component of a broader estate rather than a complete description of all Rayaldee protection. A freedom-to-operate review should examine the full family, continuation patents, Orange Book listings, and corresponding foreign rights.

Which companies are challenging the patent?

A generic applicant seeking approval for extended-release calcifediol would most likely use an ANDA and could submit a Paragraph IV certification against any listed patent. The public record must be checked for the specific ANDA, notice-letter recipient, and litigation docket before attributing a challenge to a particular company.

The commercial challenger set is likely to include manufacturers with renal and specialty-pharmaceutical portfolios, including large generic companies and vertically integrated generic suppliers. A Paragraph IV filing alone does not establish that a product will launch. Litigation, settlement terms, regulatory approval, and the remaining patent estate determine actual entry risk.

No biosimilar pathway applies. Calcifediol is a chemically synthesized small molecule, so competing products would be regulated as generics or potentially as 505(b)(2) products, not biosimilars.[4]

What generic launch scenarios exist for calcifediol?

Paragraph IV litigation

A first ANDA applicant could obtain 180 days of shared or first-applicant generic exclusivity if statutory conditions are met. The applicant would face risk under the patent’s functional pharmacokinetic limitations because a bioequivalent extended-release product may produce similar Cmax and Tmax behavior.

Section viii carve-out

A generic applicant may attempt to omit patented methods from its labeling. This strategy is more difficult where the patented method overlaps with the principal approved indication or the standard dosing regimen.

505(b)(2) pathway

A 505(b)(2) applicant could pursue a modified calcifediol product with a different release profile, dose, or indication. The applicant would still face listed-patent certifications and potential infringement exposure.

Post-expiration entry

A generic product could launch after expiration of the relevant patent and any applicable regulatory exclusivity. Remaining formulation or manufacturing patents would still require analysis.

How strong is the patent estate for extended-release calcifediol?

The estate is strongest against products that reproduce the commercial pharmacokinetic profile and use the same chronic renal indication. It is weaker against:

immediate-release calcifediol;
nonoral delivery systems;
dosing outside 1 to 100 micrograms per day;
treatment periods shorter than one month;
products that do not meet the 20% Cmax or 25% Tmax thresholds;
labels omitting the claimed treatment objectives;
formulations with materially different exposure profiles.

The central enforcement advantage is that the claims are not limited to a single excipient system. The central weakness is that infringement may require comparative clinical pharmacology evidence rather than simple label or composition comparison.

How does Rayaldee compare with competing vitamin D products?

Product or class	Active ingredient	Release profile	Main use	Relationship to US 8,778,373
Rayaldee	Extended-release calcifediol	Extended release	Secondary hyperparathyroidism with CKD and vitamin D insufficiency	Primary commercial product associated with the claims
Generic immediate-release calcifediol	Calcifediol	Immediate release	Vitamin D replacement	May avoid controlled-release limitations
Calcitriol	1,25-dihydroxyvitamin D3	Immediate or modified release	CKD-related mineral metabolism	Different active compound
Doxercalciferol	1-alpha-hydroxyvitamin D2	Immediate release	Secondary hyperparathyroidism	Different active compound
Paricalcitol	Vitamin D analog	Immediate or injectable	Secondary hyperparathyroidism	Different active compound and often different route
Nutritional vitamin D3	Cholecalciferol	Immediate or depot-like exposure	Vitamin D supplementation	Does not comprise 25-hydroxyvitamin D3 unless separately formulated

The patent does not broadly block all vitamin D therapies. Its commercial relevance is concentrated in extended-release calcifediol products and chronic treatment regimens that reproduce the claimed exposure profile.

What geographic protection exists outside the United States?

The US patent does not create rights outside the United States. The relevant international landscape depends on the patent family’s PCT filings, national-phase applications, and granted rights in Europe, Canada, Australia, Japan, and other markets.

Foreign claims may differ materially from the US claims. Some jurisdictions may have claims directed to:

the extended-release composition;
specific dissolution profiles;
manufacturing methods;
dosing regimens;
treatment of secondary hyperparathyroidism;
serum 25(OH)D targets.

International commercial risk should therefore be assessed family by family, not by assuming that the US grant was reproduced in every country.

Key Takeaways

US Patent 8,778,373 is directed to controlled-release administration of 25-hydroxyvitamin D3.
Claim 1 uses alternative pharmacokinetic limitations: reduced Cmax24hr/C24hr or increased Tmax.
Claim 9 requires at least a 20% reduction in the Cmax ratio.
Claim 17 requires at least a 25% increase in Tmax.
Dependent claims cover 1 to 100 micrograms per day, at least one month of treatment, vitamin D-deficient or replete patients, secondary hyperparathyroidism, and serum 25(OH)D targets of at least 30 ng/mL.
Rayaldee is the principal commercial product associated with the patent.
Generic risk is concentrated in extended-release calcifediol products, not ordinary calcitriol, doxercalciferol, paricalcitol, or cholecalciferol products.
The main litigation issues would involve comparator selection, pharmacokinetic testing, claim construction, validity of functional limitations, and labeling.
No biosimilar pathway applies because calcifediol is a small-molecule drug.
Patent expiry, Orange Book status, continuation patents, regulatory exclusivity, and any Paragraph IV settlement must be evaluated together before projecting generic entry.

FAQs About US Patent 8,778,373 and Calcifediol

Does US Patent 8,778,373 claim the Rayaldee capsule itself?

No. The supplied claims are method claims. They focus on administering controlled-release calcifediol and achieving specified pharmacokinetic or clinical outcomes. Separate formulation patents may protect the capsule composition or release technology.

Can an immediate-release calcifediol product infringe US Patent 8,778,373?

An immediate-release product would generally have a stronger noninfringement position against the controlled-release limitation. The final analysis would depend on the actual release behavior, labeling, and asserted claim.

What serum 25(OH)D level is relevant to the claims?

Several claims use a threshold of at least 30 ng/mL. Claims 8 and 16 tie that threshold to treatment of elevated PTH, while claim 18 addresses preventing the serum concentration from falling below 30 ng/mL.

Does a different dose automatically avoid the patent?

No. A dose outside the 1 to 100 microgram daily range may avoid claims 3, 11, and 19, but claim 1 and other claims do not necessarily contain that dose limitation.

Is a Paragraph IV challenge likely to depend on pharmacokinetic data?

Yes. Because the claims require comparative Cmax or Tmax results, a challenger would likely address pharmacokinetic equivalence, controlled-release behavior, comparator selection, and whether the claimed thresholds are inherent in the proposed product.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2023). Rayaldee (calcifediol) extended-release capsules: Prescribing information. OPKO Health, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation resources. https://www.uspto.gov/patents/laws/patent-term-adjustment
U.S. Food and Drug Administration. (2024). Generic drug user fee amendments and abbreviated new drug application resources. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
United States Patent and Trademark Office. (2014). U.S. Patent No. 8,778,373: Controlled release formulations of vitamin D compounds. https://patents.google.com/patent/US8778373B2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes	8,778,373	⤷ Start Trial				ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2481400	⤷ Start Trial	301085	Netherlands	⤷ Start Trial
European Patent Office	2481400	⤷ Start Trial	122020000079	Germany	⤷ Start Trial
European Patent Office	2481400	⤷ Start Trial	CA 2020 00059	Denmark	⤷ Start Trial
European Patent Office	2481400	⤷ Start Trial	C02481400/01	Switzerland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,778,373

Which drugs does patent 8,778,373 protect, and when does it expire?

Summary for Patent: 8,778,373